Abstract | BACKGROUND: Direct oral anticoagulants have become a standard therapy for non-valvular atrial fibrillation (NVAF). However, little is known about their effectiveness/safety when prescribed by general practitioners to treat high-risk populations such as the elderly, those who are frail or have cognitive dysfunction.Methods and Results:In this multicenter, prospective study, a total of 5,717 NVAF patients (mean age 73.9 years) receiving rivaroxaban were registered by general practitioners, with a maximum 3-year follow up (mean 2.0±0.5 years). The primary endpoint was a composite of stroke and systemic embolism (SE). The annual incidence (per 100 person-years) of stroke/SE was 1.23% and for major bleeding, it was 0.63%. Multivariate analyses identified age ≥75 years (hazard ratio [HR]; 2.67, P<0.001) and history of ischemic stroke (HR; 1.89, P=0.005) as significant risk factors of stroke/SE, with history of major bleeding (HR; 14.9, P<0.001) and warfarin use (HR; 2.15, P=0.002) as risk factors for major bleeding events. Neither cognitive dysfunction, defined by the receipt of anti- dementia medications, nor frailty, evaluated by the classification of the Japanese Long-term Care Insurance system, correlated with stroke/SE or major bleeding events. CONCLUSIONS: The low incidence of adverse events, including stroke/SE and bleeding, in patients prescribed rivaroxaban by general practitioners supports its use as a safe and efficacious treatment in the standard clinical care of high-risk patient populations.
|
Authors | Kengo Kusano, Nobuyoshi Sugishita, Masaharu Akao, Hikari Tsuji, Kunihiko Matsui, Shinya Hiramitsu, Yutaka Hatori, Hironori Odakura, Hiroyuki Kamada, Koji Miyamoto, Hisao Ogawa |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 85
Issue 8
Pg. 1275-1282
(07 21 2021)
ISSN: 1347-4820 [Electronic] Japan |
PMID | 33814525
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Rivaroxaban
|
Topics |
- Aged
- Anticoagulants
(adverse effects)
- Atrial Fibrillation
(complications, drug therapy)
- Embolism
- General Practitioners
- Hemorrhage
(chemically induced, epidemiology)
- Humans
- Japan
(epidemiology)
- Prospective Studies
- Retrospective Studies
- Rivaroxaban
(adverse effects)
- Stroke
(epidemiology, etiology, prevention & control)
- Treatment Outcome
|